KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Change in Cash (2016 - 2025)

Novavax (NVAX) has 16 years of Change in Cash data on record, last reported at -$27.3 million in Q4 2025.

  • For Q4 2025, Change in Cash rose 36.93% year-over-year to -$27.3 million; the TTM value through Dec 2025 reached -$289.2 million, down 650.92%, while the annual FY2025 figure was -$289.2 million, 650.92% down from the prior year.
  • Change in Cash reached -$27.3 million in Q4 2025 per NVAX's latest filing, down from $14.4 million in the prior quarter.
  • Across five years, Change in Cash topped out at $1.4 billion in Q1 2021 and bottomed at -$711.9 million in Q1 2023.
  • Average Change in Cash over 5 years is -$19.6 million, with a median of -$62.9 million recorded in 2023.
  • Peak YoY movement for Change in Cash: soared 1214.45% in 2021, then crashed 1374.87% in 2023.
  • A 5-year view of Change in Cash shows it stood at -$418.6 million in 2021, then surged by 113.34% to $55.8 million in 2022, then tumbled by 247.88% to -$82.6 million in 2023, then surged by 47.55% to -$43.3 million in 2024, then surged by 36.93% to -$27.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were -$27.3 million in Q4 2025, $14.4 million in Q3 2025, and -$9.5 million in Q2 2025.